Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients

Ayelet Grupper; Liane Rabinowich; Merav Ben-Yehoyada; Eugene Katchman; Roni Baruch; Tal Freund; David Hagin; Shani Ben Shlomo; Doron Schwartz; Idit F. Schwartz; Moshe Shashar; Orit Kliuk Ben Bassat; Tami Halperin; Dan Turner; Esther Saiag; Yaacov Goykhman; Oren Shibolet; Sharon Levy; Inbal Houri; Helena Katchman

doi:https://doi.org/10.1016/j.transproceed.2022.02.011

Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients

Ayelet Grupper, Liane Rabinowich, Merav Ben-Yehoyada, Eugene Katchman, Roni Baruch, Tal Freund, David Hagin, Shani Ben Shlomo, Doron Schwartz, Idit F. Schwartz, Moshe Shashar, Orit Kliuk Ben Bassat, Tami Halperin, Dan Turner, Esther Saiag, Yaacov Goykhman, Oren Shibolet, Sharon Levy, Inbal Houri, Helena Katchman

Clinical Departments

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Most solid organ transplant recipients did not develop an appreciable serologic response after 2 doses of the mRNA SARS-CoV-2 vaccine. Methods: We analyzed the humoral response after a third dose of the BNT162b2 vaccine in 130 kidney transplant recipients, compared to 48 health care workers, and associated factors, including prevaccine cellular immune response, by evaluating intracellular cytokine production after stimulation of donor's peripheral blood mononuclear cells. Results: After 2 doses, most of the controls (47 out of 48, 98%) and only 40% of kidney recipients (52 of 130) kidney recipients were seropositive (P < .001). Most seronegative recipients developed a serologic response after the booster (47 out 78, 60%), thus bringing the total number of seropositive recipients to 99 out of 130 (76%). After the third dose, there was a significant increase in antibodies titers in both groups. Decreased humoral response was significantly associated with an older age, lower lymphocyte count, and a lower level of antibodies before booster administration. CD4⁺TNFα⁺ and CD4⁺INFγ⁺ were correlated with mean increase in antibody titers. Conclusions: A third dose of the BNT162b2 mRNA vaccine in kidney recipients is safe and effectively results in increased IgG anti-S levels, including in individuals who were seronegative after 2 doses. Long-term studies of the length of the immune response and protection are required.

Original language	English
Pages (from-to)	1439-1445
Number of pages	7
Journal	Transplantation Proceedings
Volume	54
Issue number	6
DOIs	https://doi.org/10.1016/j.transproceed.2022.02.011
State	Published - 1 Jul 2022

Keywords

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines/adverse effects
COVID-19/prevention & control
Humans
Immunization, Secondary/adverse effects
Immunoglobulin G
Kidney Transplantation/adverse effects
Leukocytes, Mononuclear
RNA, Messenger
SARS-CoV-2
Transplant Recipients
Tumor Necrosis Factor-alpha
Vaccines, Synthetic
mRNA Vaccines

All Science Journal Classification (ASJC) codes

Transplantation
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1016/j.transproceed.2022.02.011

Cite this

Grupper, A., Rabinowich, L., Ben-Yehoyada, M., Katchman, E., Baruch, R., Freund, T., Hagin, D., Shlomo, S. B., Schwartz, D., Schwartz, I. F., Shashar, M., Bassat, O. K. B., Halperin, T., Turner, D., Saiag, E., Goykhman, Y., Shibolet, O., Levy, S., Houri, I., & Katchman, H. (2022). Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients. Transplantation Proceedings, 54(6), 1439-1445. https://doi.org/10.1016/j.transproceed.2022.02.011

@article{1e4ad34d48674f08bab2e45595e9c2d2,

title = "Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients",

abstract = "Background: Most solid organ transplant recipients did not develop an appreciable serologic response after 2 doses of the mRNA SARS-CoV-2 vaccine. Methods: We analyzed the humoral response after a third dose of the BNT162b2 vaccine in 130 kidney transplant recipients, compared to 48 health care workers, and associated factors, including prevaccine cellular immune response, by evaluating intracellular cytokine production after stimulation of donor's peripheral blood mononuclear cells. Results: After 2 doses, most of the controls (47 out of 48, 98%) and only 40% of kidney recipients (52 of 130) kidney recipients were seropositive (P < .001). Most seronegative recipients developed a serologic response after the booster (47 out 78, 60%), thus bringing the total number of seropositive recipients to 99 out of 130 (76%). After the third dose, there was a significant increase in antibodies titers in both groups. Decreased humoral response was significantly associated with an older age, lower lymphocyte count, and a lower level of antibodies before booster administration. CD4+TNFα+ and CD4+INFγ+ were correlated with mean increase in antibody titers. Conclusions: A third dose of the BNT162b2 mRNA vaccine in kidney recipients is safe and effectively results in increased IgG anti-S levels, including in individuals who were seronegative after 2 doses. Long-term studies of the length of the immune response and protection are required.",

keywords = "Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines/adverse effects, COVID-19/prevention & control, Humans, Immunization, Secondary/adverse effects, Immunoglobulin G, Kidney Transplantation/adverse effects, Leukocytes, Mononuclear, RNA, Messenger, SARS-CoV-2, Transplant Recipients, Tumor Necrosis Factor-alpha, Vaccines, Synthetic, mRNA Vaccines",

author = "Ayelet Grupper and Liane Rabinowich and Merav Ben-Yehoyada and Eugene Katchman and Roni Baruch and Tal Freund and David Hagin and Shlomo, {Shani Ben} and Doron Schwartz and Schwartz, {Idit F.} and Moshe Shashar and Bassat, {Orit Kliuk Ben} and Tami Halperin and Dan Turner and Esther Saiag and Yaacov Goykhman and Oren Shibolet and Sharon Levy and Inbal Houri and Helena Katchman",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jul,

day = "1",

doi = "https://doi.org/10.1016/j.transproceed.2022.02.011",

language = "الإنجليزيّة",

volume = "54",

pages = "1439--1445",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier",

number = "6",

}

Grupper, A, Rabinowich, L, Ben-Yehoyada, M, Katchman, E, Baruch, R, Freund, T, Hagin, D, Shlomo, SB, Schwartz, D, Schwartz, IF, Shashar, M, Bassat, OKB, Halperin, T, Turner, D, Saiag, E, Goykhman, Y, Shibolet, O, Levy, S, Houri, I & Katchman, H 2022, 'Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients', Transplantation Proceedings, vol. 54, no. 6, pp. 1439-1445. https://doi.org/10.1016/j.transproceed.2022.02.011

TY - JOUR

T1 - Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients

AU - Grupper, Ayelet

AU - Rabinowich, Liane

AU - Ben-Yehoyada, Merav

AU - Katchman, Eugene

AU - Baruch, Roni

AU - Freund, Tal

AU - Hagin, David

AU - Shlomo, Shani Ben

AU - Schwartz, Doron

AU - Schwartz, Idit F.

AU - Shashar, Moshe

AU - Bassat, Orit Kliuk Ben

AU - Halperin, Tami

AU - Turner, Dan

AU - Saiag, Esther

AU - Goykhman, Yaacov

AU - Shibolet, Oren

AU - Levy, Sharon

AU - Houri, Inbal

AU - Katchman, Helena

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Background: Most solid organ transplant recipients did not develop an appreciable serologic response after 2 doses of the mRNA SARS-CoV-2 vaccine. Methods: We analyzed the humoral response after a third dose of the BNT162b2 vaccine in 130 kidney transplant recipients, compared to 48 health care workers, and associated factors, including prevaccine cellular immune response, by evaluating intracellular cytokine production after stimulation of donor's peripheral blood mononuclear cells. Results: After 2 doses, most of the controls (47 out of 48, 98%) and only 40% of kidney recipients (52 of 130) kidney recipients were seropositive (P < .001). Most seronegative recipients developed a serologic response after the booster (47 out 78, 60%), thus bringing the total number of seropositive recipients to 99 out of 130 (76%). After the third dose, there was a significant increase in antibodies titers in both groups. Decreased humoral response was significantly associated with an older age, lower lymphocyte count, and a lower level of antibodies before booster administration. CD4+TNFα+ and CD4+INFγ+ were correlated with mean increase in antibody titers. Conclusions: A third dose of the BNT162b2 mRNA vaccine in kidney recipients is safe and effectively results in increased IgG anti-S levels, including in individuals who were seronegative after 2 doses. Long-term studies of the length of the immune response and protection are required.

AB - Background: Most solid organ transplant recipients did not develop an appreciable serologic response after 2 doses of the mRNA SARS-CoV-2 vaccine. Methods: We analyzed the humoral response after a third dose of the BNT162b2 vaccine in 130 kidney transplant recipients, compared to 48 health care workers, and associated factors, including prevaccine cellular immune response, by evaluating intracellular cytokine production after stimulation of donor's peripheral blood mononuclear cells. Results: After 2 doses, most of the controls (47 out of 48, 98%) and only 40% of kidney recipients (52 of 130) kidney recipients were seropositive (P < .001). Most seronegative recipients developed a serologic response after the booster (47 out 78, 60%), thus bringing the total number of seropositive recipients to 99 out of 130 (76%). After the third dose, there was a significant increase in antibodies titers in both groups. Decreased humoral response was significantly associated with an older age, lower lymphocyte count, and a lower level of antibodies before booster administration. CD4+TNFα+ and CD4+INFγ+ were correlated with mean increase in antibody titers. Conclusions: A third dose of the BNT162b2 mRNA vaccine in kidney recipients is safe and effectively results in increased IgG anti-S levels, including in individuals who were seronegative after 2 doses. Long-term studies of the length of the immune response and protection are required.

KW - Antibodies, Viral

KW - BNT162 Vaccine

KW - COVID-19 Vaccines/adverse effects

KW - COVID-19/prevention & control

KW - Humans

KW - Immunization, Secondary/adverse effects

KW - Immunoglobulin G

KW - Kidney Transplantation/adverse effects

KW - Leukocytes, Mononuclear

KW - RNA, Messenger

KW - SARS-CoV-2

KW - Transplant Recipients

KW - Tumor Necrosis Factor-alpha

KW - Vaccines, Synthetic

KW - mRNA Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85127306033&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.transproceed.2022.02.011

DO - https://doi.org/10.1016/j.transproceed.2022.02.011

M3 - مقالة

C2 - 35346486

SN - 0041-1345

VL - 54

SP - 1439

EP - 1445

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 6

ER -

Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this